[artículo]
| Título : |
Reboxetine, a new noradrenaline selective antidepressant, is at least as effective as fluoxetine in the treatment of depression |
| Tipo de documento: |
texto impreso |
| Autores: |
Vittorino Andreoli, Autor ; Vincent Caillard, Autor ; Ripu S. Deo, Autor |
| Fecha de publicación: |
2023 |
| Artículo en la página: |
pp. 393-399 |
| Idioma : |
Inglés (eng) Idioma original : Inglés (eng) |
| Palabras clave: |
Antidepresivos, Trastorno depresivo mayor, Fluoxetina, Morfolinas, Reboxetina, Inhibidores selectivos de la recaptación de serotonina. |
| Resumen: |
The clinical profile of reboxetine, a selective noradrenaline reuptake inhibitor, was compared with that of the selective serotonin reuptake inhibitor fluoxetine and placebo in a double-blind, multicenter, parallel-group clinical trial of patients with major depression. |
| Link: |
./index.php?lvl=notice_display&id=31056 |
in Journal of Clinical Psychopharmacology > Año 2002 - Vol. 22 - No. 4 (Agosto) . - pp. 393-399
|
Reboxetine, a new noradrenaline selective antidepressant, is at least as effective as fluoxetine in the treatment of depression en Journal of Clinical Psychopharmacology, Año 2002 - Vol. 22 - No. 4 (Agosto)
